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Abstract
It was suggested that statin may improve the outcomes of pneumonia patients. However, there are sparse data regarding this topic in ethnic
Chinese populations. In the present study, we investigated associations between previous statin use and pneumonia outcomes in Taiwan
with a large-scale matched cohort study. A total of 11 576 patients with pneumonia were selected, comprising 2894 patients with previous
statin use and 8682 matched patients. We used a separate conditional logistic regression to explore relationships between statin use and
each clinical outcome, including ‘intensive care unit admission,’ ‘use of mechanical ventilation,’ ‘acute respiratory failure’ and ‘in-hospital
death’. We found that patients who were statin users were 0.81 (95% CI 0.74–0.89), 0.80 (95% CI 0.71–0.89), 0.84 (95% CI 0.75–0.94) and
0.69 times (95% CI 0.57–0.85) less likely to be admitted to the intensive care unit, to have acute respiratory failure, to need mechanical
ventilation, and to die in the hospital, respectively, than patients who were not statin users. In addition, it consistently revealed that
compared with patients who were not statin users, regular statin users had lower ORs of intensive care unit admission, acute respiratory
failure, the use of mechanical ventilation and in-hospital death. However, there were no signiﬁcant differences in the above adverse
outcomes between irregular users of statin and non-statin users. We concluded that patients with regular previous statin use were
signiﬁcantly associated with favourable outcomes during admission for pneumonia in Taiwan.
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Introduction
Statin, a 3-hydroxy-3methylglutaryl-coenzyme reductase inhib-
itor, is a well-known lipid-lowering agent and has been clinically
applied in primary and secondary prevention of cardiovascular
diseases [1–4]. It is worth noting that a body of evidence
demonstrated that statin also exhibits pleiotropic effects
particularly in immnuomodulation, which can modulate
pro-inﬂammatory responses and mediators [5–7]. Statin may
restore endothelial dysfunction in certain pathological condi-
tions [8,9]. In addition, antimicrobial effects were reported for
statin [10]. Therefore, the therapeutic role of statin has been
investigated to treat severe inﬂammatory responses and
diffuse endothelial dysfunction in patients with sepsis [11].
Statin was also reported to be associated with decreased
prevalence and improved outcomes of pneumonia [10].
Although a recent meta-analysis suggested that statin was
associated with lower short-term mortality in patients with
pneumonia, the beneﬁcial effects were diminished in a
subgroup analysis with confounding factors [12].
Most of the data regarding statin use in the treatment of
infectious diseases were obtained in Western populations.
Very few studies have investigated similar effects in ethnic
Chinese populations. Yang et al. [13] reviewed the effect of
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pre-admission statin use on short-term survival in patients
with sepsis in a hospital-based retrospective study and found
no beneﬁcial effect in reducing mortality in those patients.
They concluded that statin may have little protective effect
against infectious diseases in an ethnic Chinese population. In
other words, the beneﬁcial effects of statin in treating
infectious diseases may have signiﬁcant ethnic differences.
Statin is a commonly prescribed medication in clinical
settings. Ethnic differences should be further investigated
before applying the results of the previous study to ethnic
Chinese populations. For this reason, we conducted a
large-scale study based on a nationwide sample in Taiwan to
study whether statin is associated with favourable outcomes in
pneumonia patients.
Methods
Database
The study sample for this matched cohort study was retrieved
from Taiwan’s Longitudinal Health Insurance Database 2000;
this includes medical beneﬁt claims and registration ﬁles for
1 000 000 individuals under the Taiwan National Health
Insurance (NHI) programme. Some researchers and the
Taiwan National Health Institute have demonstrated the high
validity of the data from the NHI programme [14,15]. To date,
hundreds of studies using the data from the NHI programme
have been published in internationally peer-reviewed journals
[16].
Study sample
We identiﬁed 23 914 hospitalizations with a principal diagnosis
of pneumonia (International Classiﬁcation of Disease, 9th
revision CM 480–483.8, 485–487.0) from January 2008 to
December 2011. If a patient had more than one admission for
treatment of pneumonia during the study period, we only
included the ﬁrst episode for inclusion in the study sample
(n = 16 285). In addition, we excluded patients <40 years old
(n = 3221) because the prevalence of statin use is very low in
this age group. As a result, 14 064 pneumonia hospitalizations
were identiﬁed. Of these pneumonia patients, 2894 had been
prescribed statin for more than 1 month within 6 months of
their index pneumonia admission. To be included in this
analysis, a subject had to have been prescribed statin for at
least 1 month within 6 months of the index pneumonia
admission. Ultimately, 2894 patients who were prescribed
statin were included in our study cohort.
The comparison cohort was extracted from the remaining
11 170 pneumonia patients. We ﬁrst excluded all subjects who
had ever been prescribed statin before the index pneumonia
admission. As gender and age are the important risk factors for
pneumonia outcomes, we then randomly selected 8682
comparison patients (three for every patient in the study
group) matched with the study cohort in terms of gender and
age group (40–44, 45–49, 50–54, 55–59, 60–64, 65–69, and
>69 years).
Key variables of interest
The primary study outcomes selected in this study were based
on a previous study [17]. They were all binary variables,
including clinical outcomes of ‘intensive care unit (ICU)
admission’, ‘use of mechanical ventilation’, ‘acute respiratory
failure’ and ‘in-hospital death’. We deﬁned in-hospital death as
‘the death of a patient during hospitalization or within 3 days
after discharge’. As most Taiwanese prefer to die at home, we
also included those who died within 3 days of discharge. In
addition, acute respiratory failure is the clinical coding
commonly referring to hypoxia (usually PaO2 <60 mmHg)
and/or hypercapnia (usually PaCO2 >50 mmHg) in blood gas
examinations. Mechanical ventilator use refers to invasive
mechanical ventilator. The independent variable of interest
was whether or not a pneumonia patient was a statin user
before their index pneumonia admission. We also deﬁned
subjects who had received continuous statin prescriptions for
≥60 days within 6 months before the index date as regular
statin users. All other subjects who had been prescribed statin
within 6 months before the index date were deﬁned as
irregular statin users.
In this study, we also considered potential confounders
including the characteristics of patients and physicians in the
regression modelling. Patient characteristics included gender,
age group and the Charlson Comorbidities Index (CCI) score.
Physician characteristics consisted of gender, age and specialty
(pulmonary or critical care medicine versus other specialties).
Furthermore, we calculated a propensity score for each
patient. Because our study samples comprised medical records
obtained from the secondary database, pneumonia patients
who were and were not statin users might differ substantially
in their observed covariates. Hence, we attempted to balance
these differences in observed baseline characteristics before
the index date by calculating the propensity score so that these
two cohorts would function similarly to a randomized
controlled trial. Put simply, the propensity scores are basically
the probabilities of subjects being allocated to a certain cohort.
By conditioning on the propensity score, the distribution of
measured baseline characteristics of the statin users was
similar to that of the non-statin users. As suggested by Austin
et al. [18], all variables that are possibly related to the outcome
should be considered as a factor for the propensity score,
otherwise biased results may be obtained. The propensity
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score was therefore calculated as a function of the demo-
graphic characteristics including monthly income, residential
urbanization and residential region. With the above-mentioned
propensity score matching method, the selection bias due to
the observed covariates can be removed and a fair comparison
can be made with the cohorts of subjects who have been
assigned to the study cohort or the comparison cohort.
Statistical analysis
We used the SAS statistical package to perform all analyses.
We used separate conditional logistic regressions (stratiﬁed by
patient gender and age group) to explore relationships
between statin use and each of the clinical outcomes after
adjusting for patient and physician characteristics as well as
clustering of patients within physician panels (physician-level
random effect). A two-sided p value of <0.05 was considered
statistically signiﬁcant for this study.
Results
Table 1 presents the distributions of patient and physician
characteristics for the study and comparison cohorts. It shows
that after matching for gender and age group, patients who
were prescribed statin were less likely to have a CCI score of
0 than patients who were not prescribed statin.
Table 2 consistently reveals that patients who were statin
users had a signiﬁcantly lower likelihood of an ICU admission
(p <0.001), acute respiratory failure (p 0.007), use of mechan-
ical ventilation (p 0.003) and in-hospital death (p 0.007) than
patients who were not statin users. Conditional logistic
regression analyses (stratiﬁed by gender and age group)
suggested that patients who were statin users were 0.83 (95%
CI 0.76–0.91), 0.86 (95% CI 0.77–0.97), 0.88 (95% CI 0.78–0.98)
and 0.77 (95% CI 0.63–0.95) times less likely to be admitted to
the ICU, to have acute respiratory failure, to need mechanical
ventilation, and to die in the hospital, respectively, than patients
who were not statin users after adjusting for patients’ CCI
score and propensity score, physician’s age, gender and
specialty, and clustering effects among patients treated by any
given physician. We also found that all statin users continued to
use statin during their index hospitalizations.
Table 3 further presents the ORs of ICU admission, acute
respiratory failure, the use of mechanical ventilation and
in-hospital death for regular and irregular statin users. It
consistently revealed that compared with patients who were
not statin users, regular statin users had lower ORs of ICU
admission, acute respiratory failure, the use of mechanical
ventilation and in-hospital death. However, there were no
signiﬁcant differences in the ORs of ICU admission, acute
respiratory failure, the use of mechanical ventilation and
in-hospital death between irregular statin users and non-statin
users after adjusting for patients’ CCI score and propensity
score, physician age, gender and specialty, and clustering
effects among patients treated by any given physician.
Table 4 shows the ORs for adverse clinical outcome by age
group. We found that of the pneumonia patients ≤64 years
old, statin users were less likely to be admitted to the ICU, to
have acute respiratory failure, to need mechanical ventilation
and to die in the hospital compared with patients who were
not statin users. However, of the patients who were >64 years
old, there were no signiﬁcant differences in the ORs of acute
respiratory failure and in-hospital death between patients who
were and were not statin users.
Table 5 further presents the ORs for adverse clinical
outcome by CCI score. Of the pneumonia patients who had
CCI score >1, patients who were statin users had consistently
lower ORs of all adverse clinical outcomes than comparison
patients. Because pneumonia has different prevalence among
the different seasons, we further analysed the seasonal pattern
of death for pneumonia between the two groups. Fig. 1 shows
that there is a similar seasonal pattern of death for pneumonia
in pneumonia patients who were statin users and the
comparison group.
TABLE 1. Demographic characteristics of pneumonia
patients who were and were not statin users (n = 11 576)
Variable
Patients who
were statin
users
(n = 2894)
Comparison
cohort
(n = 8682)
p valueTotal no. % Total no. %
Patient characteristics
Gender
Male 1556 53.8 4668 53.8 >0.999
Female 1338 46.2 4014 46.2
Age (years)
40–44 39 1.3 117 1.2 >0.999
45–49 58 2.0 174 2.0
50–54 149 5.1 447 5.2
55–59 193 6.7 579 6.7
60–64 255 8.8 765 8.5
65–69 288 10.0 864 10.0
>69 1912 66.1 5736 66.4
Charlson Comorbidity Index score
0 716 24.7 3038 35.0 <0.001
1 1114 38.5 3117 35.9
2 659 22.8 1292 14.9
3 222 7.7 566 6.5
≥4 183 6.3 669 7.7
Physician characteristics
Gender
Male 2665 92.1 8026 92.6 0.531
Female 229 7.9 656 7.4
Age (years)
<40 1050 36.3 2944 33.9 0.051
40–49 1173 40.5 3595 41.4
>49 671 23.2 2143 24.7
Physician specialty
Pulmonary or Critical
Care Medicine
732 25.3 2503 28.8 <0.001
Others 2162 74.7 6179 71.2
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Discussion
We found that previous statin use was signiﬁcantly associated
with lower frequencies of the need for mechanical ventilation,
ICU admission, acute respiratory failure and in-hospital death
in hospitalized patients with pneumonia in Taiwan. This ﬁnding
is consistent with most previous observations in Western
populations. The beneﬁcial effects of statin on infectious
diseases in an ethnic Chinese population are still unclear.
Contradictory to our ﬁndings, Yang et al. reported no
signiﬁcant improvement in short-term mortality in septic
patients with previous statin use in a retrospective
hospital-based study in Taiwan. The authors hypothesized that
beneﬁcial effects of statin against infectious diseases may be
weaker in ethnic Chinese populations [13]. However, the
results of their study may have suffered from a relatively small
sample size and potential selection bias. The different inclusion
criteria of patients also partially explain the results of their
study. Another recent retrospective study performed in
Taiwan comprising 14 316 patients with chronic obstructive
pulmonary disease showed that statin users were signiﬁcantly
associated with lower admission rates due to chronic
obstructive pulmonary disease exacerbation [19]. Coexisting
respiratory infection plays an important role in chronic
obstructive pulmonary disease exacerbation. Therefore, their
TABLE 2. Crude ORs for adverse clinical outcomes for pneumonia patients who were statin users
Presence of adverse clinical outcomes
Total sample
n = 11 576
Patients who were
statin users n = 2894
Comparison group
n = 8682
No. % No. % No. %
Intensive care unit admission
Yes 3768 32.5 842 29.1 2926 33.7
Crude OR (95% CI) – 0.81*** (0.74–0.89) 1.00
Adjusted OR (95% CI) – 0.83*** (0.76–0.91) 1.00
Acute respiratory failure
Yes 2069 17.9 447 15.5 1622 18.7
Crude OR (95% CI) – 0.80*** (0.71–0.89) 1.00
Adjusted OR (95% CI) – 0.86** (0.77–0.97) 1.00
Mechanical ventilation
Yes 2026 17.5 453 15.7 1573 18.1
Crude OR (95% CI) – 0.84** (0.75–0.94) 1.00
Adjusted OR (95% CI) – 0.88* (0.78–0.98) 1.00
In-hospital death
Yes 651 5.6 124 4.3 527 6.1
Crude OR (95% CI) – 0.69*** (0.57–0.85) 1.00
Adjusted OR (95% CI) – 0.77* (0.63–0.95) 1.00
*p <0.05; **p <0.01; ***p <0.001.
Adjusted ORs were calculated by a conditional logistic regression (conditioned on gender and age group) to adjust for patients’ Charlson Comorbidity Index score, physicians’ age,
gender and specialty, propensity score, and clustering effects of physicians.
TABLE 3. Crude ORs for adverse clinical outcomes for pneumonia patients who were regular or irregular statin users
Presence of adverse clinical outcomes
Patients who were
regular statin users
n = 2405
Patients who were
irregular statin users
n = 489
Comparison group
n = 8082
No. % No. % No. %
Intensive care unit admission
Yes 695 28.9 147 30.1 2717 33.6
Crude OR (95% CI) 0.80*** (0.72–0.88) 0.85 (0.69–1.03) 1.00
Adjusted OR (95% CI) 0.83*** (0.75–0.92) 0.83 (0.68–1.01) 1.00
Acute respiratory failure
Yes 364 15.1 83 17.0 1500 18.6
Crude OR (95% CI) 0.78*** (0.69–0.88) 0.89 (0.70–1.13) 1.00
Adjusted OR (95% CI) 0.86* (0.76–0.97) 0.93 (0.73–1.19) 1.00
Mechanical ventilation
Yes 357 14.8 96 19.6 1461 18.1
Crude OR (95% CI) 0.79*** (0.70–0.89) 1.10 (0.88–1.39) 1.00
Adjusted OR (95% CI) 0.83** (0.73–0.94) 1.12 (0.87–1.41) 1.00
In-hospital death
Yes 95 3.9 29 4.5 486 6.0
Crude OR (95% CI) 0.64*** (0.51–0.80) 0.98 (0.66–1.43) 1.00
Adjusted OR (95% CI) 0.71*** (0.57–0.89) 1.10 (0.75–1.63) 1.00
*p <0.05; **p <0.01; ***p <0.001.
Adjusted ORs were calculated by a conditional logistic regression (conditioned on gender and age group) to adjust for patients’ Charlson Comorbidity Index score, physicians’ age,
gender and specialty, propensity score, and clustering effects of physicians.
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data may be partially attributed to the protective effects of
statin against infectious respiratory diseases. Our study can
provide supportive evidence of this theory. We suggest that
statin may also have consistent protective effects against
infectious diseases, particularly pneumonia, in ethnic Chinese
and Western populations.
Some authors suggested that retrospective observational
studies may be confounded by a potential ‘healthy user bias’
[20]. Patients who regularly take statin may have more
health-promoting behaviours such as smoking cessation,
exercise, or vaccination, which may protect them from further
infectious diseases. In our study, we attempted to adjust for
underlying conditions, demographic characteristics and physi-
cian characteristics, which appeared to affect the outcomes of
patients with pneumonia using a multivariate analysis. We also
used a propensity score to minimize confounding effects of the
TABLE 4. Crude ORs for adverse clinical outcomes for pneumonia patients who were statin users by age group
Presence of adverse clinical outcomes
Age group
≤64 years >64 years
Patients who
were statin users
n = 694
Comparison
group n = 2082
Patients who
were statin users
n = 2200
Comparison
group n = 6600
No. % No. % No. % No. %
Intensive care unit admission
Yes 125 18.0 458 22.6 717 32.6 2468 37.1
Crude OR (95% CI) 0.76* (0.61–0.94) 1.00 0.82*** (0.74–0.91) 1.00
Adjusted OR (95% CI) 0.71* (0.56–0.89) 1.00 0.85*** (0.77–0.95) 1.00
Acute respiratory failure
Yes 68 9.8 206 10.1 379 17.2 1416 21.3
Crude OR (95% CI) 0.96 (0.72–1.29) 1.00 0.77*** (0.68–0.87) 1.00
Adjusted OR (95% CI) 0.96 (0.71–1.30) 1.00 0.84** (0.74–0.96) 1.00
Mechanical ventilation
Yes 65 9.4 250 12.3 388 17.6 1323 19.9
Crude OR (95% CI) 0.74* (0.55–0.98) 1.00 0.86* (0.76–0.98) 1.00
Adjusted OR (95% CI) 0.74* (0.55–0.98) 1.00 0.89* (0.78–0.99) 1.00
In-hospital death
Yes 18 2.6 84 4.1 106 4.8 443 6.7
Crude OR (95% CI) 0.62 (0.37–1.04) 1.00 0.71** (0.57–0.88) 1.00
Adjusted OR (95% CI) 0.85 (0.49–1.46) 1.00 0.80* (0.64–0.99) 1.00
*p <0.05; **p <0.01; ***p <0.001.
Adjusted ORs were calculated by a conditional logistic regression (conditioned on gender) to adjust for patients’ Charlson Comorbidity Index score, physicians’ age, gender and
specialty, propensity score, and clustering effects of physicians.
TABLE 5. Crude ORs for adverse clinical outcomes for pneumonia patients who were statin users by Charlson Comorbidity
Index score
Presence of adverse clinical outcomes
Charlson Comorbidity Index score
≤1 >1
Patients who
were statin users
n = 1830
Comparison
group n = 6155
Patients who
were statin users
n = 1064
Comparison
group n = 2527
No. % No. % No. % No. %
Intensive care unit admission
Yes 511 27.9 2050 33.3 331 31.1 876 34.7
Crude OR (95% CI) 0.78*** (0.69–0.87) 1.00 0.85* (0.73–0.99) 1.00
Adjusted OR (95% CI) 0.83* (0.73–0.93) 1.00 0.85* (0.73–0.99) 1.00
Acute respiratory failure
Yes 301 16.5 1188 19.3 146 13.7 434 17.2
Crude OR (95% CI) 0.82** (0.72–0.95) 1.00 0.77* (0.63–0.94) 1.00
Adjusted OR (95% CI) 0.93 (0.81–1.07) 1.00 0.79* (0.64–0.97) 1.00
Mechanical ventilation
Yes 301 16.5 1161 18.9 152 14.3 412 16.3
Crude OR (95% CI) 0.85* (0.74–0.97) 1.00 0.86* (0.76–0.98) 1.00
Adjusted OR (95% CI) 0.90 (0.78–1.04) 1.00 0.88 (0.72–1.08) 1.00
In-hospital death
Yes 85 4.6 347 5.6 39 3.7 180 7.1
Crude OR (95% CI) 0.82 (0.64–1.04) 1.00 0.50*** (0.35–0.71) 1.00
Adjusted OR (95% CI) 0.97 (0.76–1.24) 1.00 0.56** (0.39–0.80) 1.00
*p <0.05; **p <0.01; ***p <0.001.
Adjusted ORs were calculated by a conditional logistic regression (conditioned on gender and age group) to adjust for physicians’ age, gender, and specialty, propensity score, and
clustering effects of physicians.
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underlying conditions of patients. A propensity score analysis
provides a robust tool for adjusting for potential confounding
factors in non-randomized observational studies [21].
Although our study can provide sufﬁcient statistical power to
elucidate the association between statin use and outcomes
with pneumonia, the ‘healthy user bias’ still cannot be totally
excluded because some variables could not be obtained or
adjusted for in a retrospective study.
The dose–response of statin may be an important factor
affecting outcomes when treating infectious diseases. Because
the dose varies among different types of statins, it is difﬁcult to
pool all the data to compare the dose-dependent effects of
statin. In our study, we further classiﬁed patients taking statin
into regular and irregular users. Interestingly, we found that
regular statin users were signiﬁcantly associated with less-ad-
verse outcomes compared with the control population.
However, irregular statin users exhibited no differences in
adverse outcomes compared with patients without statins.
This ﬁnding implies that dose-dependent effects of statin may
exist when treating pneumonia.
Although there is still some controversy, a recent
meta-analysis showed that statin may improve outcomes in
pneumonia patients with pooled data [12]. The majority of
large-population retrospective studies showed positive effects
of statin in improving pneumonia outcomes. For example,
Mortensen et al. conducted a large retrospective study on
8652 patients with inﬂuenza and pneumonia in the USA. They
found signiﬁcantly decreased 30-day mortality in patients with
statin [22]. Similarly, Nielsen et al. reported consistent results
in a large-scale retrospective study in Denmark [23]. It is
worth noting that most of the data came from Western
populations. In addition, three of 13 studies reviewed reported
no signiﬁcant difference in outcomes between statin and
non-statin users [24–26]. Nevertheless, a randomized control
trial to investigate the relevant topic is still lacking. Makris et al.
[27] showed that use of pravastatin was associated with
favourable outcomes with ventilator-associated pneumonia in
an open-label, randomized study. In contrast, a recent
randomized control trial by Papazian et al. [28] showed no
signiﬁcant improvement in 28-day mortality of patients with
ventilator-associated pneumonia and statin. The discrepancy of
these results may reﬂect differences in inclusion criteria and
selection of statin among studies.
Since information on microorganisms was not available and
is important in terms of risk of death, we analysed the
seasonality of death for pneumonia patients who were statin
users and the comparison group. Viral infections such as
inﬂuenza are prevalent in the winter so winter may serve as a
proxy for viral infections. We proposed that statin may also
have protective effects against virus-associated pneumonia.
Nevertheless, further study is necessary to explore this issue.
Our study has several limitations. First, detailed clinical
parameters such as laboratory and imaging ﬁndings were not
recorded in the registry. Therefore, the degree of severity and
pathogens of pneumonia could not be determined in the
present study. Lacking this information makes it difﬁcult to
further explain the mechanism of the protective effects of
statin. Second, in this study, we pooled all statin users to
obtain sufﬁcient statistical power, which may have increased
the heterogeneity of the sample population. Further studies
are advised to explore the effects of different types of statin.
Conclusions
We found that regular previous statin use was signiﬁcantly
associated with decreased frequencies of the use of mechanical
ventilator, ICU admission, acute respiratory failure and in-hos-
pital death in hospitalized patients with pneumonia with a large
population-based study in Taiwan. A randomized-control study
is still advised to conﬁrm the beneﬁcial effects of statin in
treating infectious diseases in ethnic Chinese populations.
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